Also found in: Dictionary, Thesaurus, Wikipedia.
Related to Keflex: cephalexin


trademark for preparations of cephalexin, an oral cephalosporinantibiotic.


Apo-Cephalex, Biocef, Dom-Cephalexin, Keflex, Novo-Lexin, Nu-Cephalex, Panixine DisperDose, PMS-Cephalexin

Pharmacologic class: First-generation cephalosporin

Therapeutic class: Anti-infective

Pregnancy risk category B


Interferes with bacterial cell-wall synthesis, causing cell to rupture and die. Active against many gram-positive bacteria; shows limited activity against gram-negative bacteria.


Capsules: 250 mg, 500 mg, 750 mg

Oral suspension: 125 mg/5 ml, 250 mg/5 ml

Tablets: 250 mg, 500 mg

Indications and dosages

Respiratory tract infections caused by streptococci; skin and skin-structure infections caused by methicillin-sensitive staphylococci and streptococci; bone infections caused by methicillin-sensitive staphylococci or Proteus mirabilis; genitourinary infections caused by Escherichia coli, P. mirabilis, and Klebsiella species; Haemophilus influenzae, methicillin-sensitive staphylococcal, streptococcal, and Moraxella catarrhalis infections
Adults: 1 to 4 g P.O. daily in divided doses (usually 250 mg P.O. q 6 hours). For uncomplicated cystitis, skin and soft-tissue infections, and streptococcal pharyngitis, 500 mg P.O. q 12 hours.
Children: 25 to 50 mg/kg/day P.O. in divided doses

Otitis media caused by S. pneumoniae
Children: 75 to 100 mg/kg/day P.O. in four divided doses

Dosage adjustment

• Renal impairment


• Hypersensitivity to cephalosporins or penicillin


Use cautiously in:
• renal impairment, phenylketonuria
• history of GI disease
• debilitated or emaciated patients
• elderly patients
• pregnant or breastfeeding patients.


• Give with or without food.
• Refrigerate oral suspension.

Adverse reactions

CNS: fever, headache, lethargy, paresthesia, syncope, seizures

CV: edema, hypotension, vasodilation, palpitations, chest pain

EENT: hearing loss

GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis

GU: vaginal candidiasis, nephrotoxicity

Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression

Musculoskeletal: joint pain

Respiratory: dyspnea

Skin: rash, maculopapular and erythematous urticaria

Other: superinfection, chills, pain, allergic reaction, hypersensitivity reactions including anaphylaxis, serum sickness


Drug-drug.Aminoglycosides, loop diuretics: increased risk of nephrotoxicity

Chloramphenicol: antagonistic effect

Probenecid: increased cephalexin blood level

Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, lactate dehydrogenase, lymphocytes: increased values
Coombs' test: false-positive result (especially in neonates whose mothers received drug before delivery)

Granulocytes, neutrophils, white blood cells: decreased counts

Patient monitoring

• Assess for signs and symptoms of serious adverse reactions, including hypersensitivity, severe diarrhea, and bleeding.
• During long-term therapy, monitor CBC and liver and kidney function test results.

Patient teaching

Instruct patient to stop taking drug and contact prescriber immediately if he develops rash or difficulty breathing.
• Tell patient to take drug with full glass of water.
• Advise patient to report severe diarrhea.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


A trademark for the drug cephalexin.


a trademark for an antibacterial (cephalexin).


A brand name for CEPHALEXIN (cefalexin).
References in periodicals archive ?
The increase in the 2009 first quarter cost of goods sold is due primarily to ex-factory sales of MOXATAG in preparation for its launch in March 2009, partially offset by obsolete immediate-release KEFLEX inventory provisions expensed during the first quarter of 2008.
Total revenue for 2008 is expected to be approximately $10 million to $12 million, resulting from Keflex product sales and assuming no generic competition to Keflex 750 mg capsules occurs during the year.
The Company currently markets the Keflex brand of cephalexin and has received regulatory approval for Moxatag - the first and only once-daily amoxicillin product approved for marketing in the U.
For MRSA strains, the [minimum inhibitory concentrations] against Keflex and other [beta]-lactams are so high you would never want to rely on those drugs for a complicated infection," he said at the meeting, jointly sponsored by the Texas Medical Association.
KEFLEX, KEFLEX 750 MG, MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc.
0 million as a result of declining Keflex prescriptions due to the lower number of physician detail calls made as a result of the reduction in the size of the Company's contract sales force.
The decrease in the 2009 fourth quarter R&D expenses is primarily due to the reclassification of all personnel and related expenses from R&D to Selling, general and administrative (SG&A) after the Company indefinitely delayed the development of its KEFLEX PULSYS product candidate following the FDA's response to the Company's Special Protocol Assessment for the KEFLEX PULSYS development program.
MiddleBrook currently markets MOXATAG - the first and only FDA-approved once-daily amoxicillin - and KEFLEX, the immediate-release brand of cephalexin.
MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG -the first and only FDA-approved once-daily amoxicillin.
MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG--the first and only FDA-approved once-daily amoxicillin.
MiddleBrook currently markets KEFLEX (cephalexin, USP), the immediate-release brand of cephalexin, and MOXATAG-the first and only FDA-approved once-daily amoxicillin.
Of the approximately $100 million of gross proceeds received from EGI, MiddleBrook has used (i) approximately $11 million to repurchase its Keflex assets previously sold to certain funds affiliated with Deerfield Management, and to terminate its ongoing royalty obligations to certain Deerfield entities, and (ii) approximately $8.